key: cord-0896062-4lsvy7jq authors: Vlasschaert, Caitlyn; Topf, Joel; Hiremath, Swapnil title: Proliferation of Papers and Preprints during the COVID-19 Pandemic: Progress or Problems with Peer Review? date: 2020-08-06 journal: Adv Chronic Kidney Dis DOI: 10.1053/j.ackd.2020.08.003 sha: 5267fc9012920c4c482260f20a584b02b44c922e doc_id: 896062 cord_uid: 4lsvy7jq Abstract The COVID-19 pandemic has spread exponentially throughout the world in a short period, aided by our hyperconnected world including global trade and travel. Unlike previous pandemics, the pace of the spread of the virus has been matched by the pace of publications, not just in traditional journals, but also in preprint servers. Not all publication findings are true, and sifting through the firehose of data has been challenging to peer reviewers, editors, as well as to consumers of the literature i.e. scientists, health care workers, and the general public. There has been an equally exponential rise in the public discussion on social media. Rather than decry the pace of change, we suggest the nephrology community should embrace it, making deposition of research into preprint servers the default, encouraging pre-publication peer review more widely of such preprint studies, and harnessing social media tools to make these actions easier and seamless. The goal of research in medicine consists not just to conduct experiments and clinical studies to expand knowledge, but also to have that knowledge change and improve clinical practice. For research to matter it must go beyond knowledge generation and include knowledge dissemination and translation. The Coronavirus Disease 2019 (COVID-19) pandemic is a case study for how these ever-changing aspects of medical research are accelerating. New information is emerging at lightning-fast pace, creating the world's first infodemic 1, 2 . The face of primary literature is evolving with the emergence of preprints alongside peer-reviewed journal articles, all of which is discussed and debated publicly and privately over internet-based communication channels including social media such as Twitter, YouTube, podcasts, and blog posts. The need for speed in disseminating data as soon as it is generated is indeed very high, but the responsibility for critical analysis of the data before translating into action is just as high. How do we tread through the emerging evidence to update the collective medical knowledge base while ensuring safe, timely communication of important updates to the public? In this review, we examine publishing in the COVID-19 era: from emerging data and clinical challenges, to new resources and public outreach measures. Social media has enhanced our collective understanding of this disease and allowed us to better communicate with people living with kidney disease. Never before has our collective scientific focus been so concentrated and the output so voluminous. As shown in Figure 1A , nearly 20,000 unique manuscripts have been published on COVID-19 as of June 2020, with the ongoing addition of more than 2,000 papers every week. This growing body of literature includes both papers published in traditional journals-some having undergone rapid peer review-and preprinted material. Preprints are non-peer reviewed manuscripts that are publicly posted on the internet in order to more rapidly disseminate important findings to the scientific community. In theory, these preprints can undergo pre-publication peer review, with a comment section open to everyone for providing feedback. Most journals, including in nephrology, do accept preprints and do not consider them as prior publications. 3 Preprints can make data available essentially as soon as it is generated, to everyone, including fellow scientists, healthcare workers, and the general public, all without any paywall or subscription fees. During the COVID-19 pandemic, expediting data availability has enabled early epidemiological modeling 4,5 and accelerated our understanding of COVID-19 pathogenicity 6 . Preprints are not new. The first preprint server, arXiv (pronounced "archive"), was created in 1991 as a repository for physics, computer science and mathematics papers. Many fields (and some countries) now have dedicated preprint servers, including bioRxiv 7 for the biological sciences and medRxiv 8 for clinical and health sciences. While preprints had been gaining steady traction prior to the COVID-19 pandemic 9 -including in kidney disease research 10 -they have drawn unprecedented attention in the last few months. They are open, fast, and free, which does create a different set of problems. The speed at which preprinted manuscripts become available is counterbalanced by a lack of peer review and of editorial discretion about packaging of the knowledge without making extraordinary claims. Indeed, the ease of uploading a manuscript to a preprint server has been misused to postulate bold claims without sufficient supporting evidence, such as a preprint purporting that four inserts in the COVID-19 virus were similar to the human immunodeficiency virus-1 (HIV-1) and hence unlikely to be 'fortuitous' 11 . Critiques of this preprint on microblogging websites such as Twitter and Sina Weibo, as well as on independent peer review platforms 12 , led to its swift withdrawal, however it is quite likely that many other erroneous findings abound. 13 Another issue is that preprints can lead outside investigators to double count the results. If a researcher is trying to collate research as part of a narrative or quantitative synthesis and counts a peer-reviewed article, they should ignore the associated preprint to avoid overweighting that cohort. Ideally preprint servers identify when the paper gets published, but this automatic linking depends on the title and authors remaining the same, and may fail if these change from preprint to peer-review. Similarly, the journal concerned should identify the preprint version as part of the publication record, which should, but does not always happen 14 . MedRxiv has screening measures to mitigate the spread of medical misinformation 15 , which include barring in silico drug prediction work. 16 In silico work uses computer modeling to suggest possible drug therapies for a disease, and can hence be quite misleading. Until the COVID-19 pandemic, preprint uptake in the medical field had been slow, with only a handful of early adopters. Hence, the problem of critical appraisal and data quality had not been a major concern. Now, given the flood of data, interest in COVID-19 concerns about medical misinformation are both valid and critical. This needs to be addressed by the wider scientific community. A study on preprint usage, itself posted on a preprint server, provides some more data, and potentially reassurance about proliferation of preprints during this pandemic 17 . The study reports that approximately 40% of all articles published during the COVID-19 pandemic (6,000 of 16,000) have been initially uploaded to a preprint server. The rate of publication of preprints was also several magnitudes higher than previous epidemics (2,527 in the initial 4 months on two servers compared to 78 for Zika and 10 for Ebola). Intriguingly, COVID-19 preprints were 2711 words shorter in length than non-COVID-19 preprints (median, 3432 vs 6143; p < 0.001). The authors hypothesize that this supports anecdotal observations, in that preprints are being used to share more work-in-progress data than a complete story. About 4% of the preprints had been published in traditional journals by the end of the study period (end of April 2020), with little change between the preprint version and published J o u r n a l P r e -p r o o f version. They also note that the preprint on HIV and COVID-19, which was quickly retracted, had 127 comments, suggesting controversial data is being rapidly and publicly scrutinised. Some preprints, purporting that COVID-19 poses less of a threat than vehicular accidents 18 or inferring an infection fatality rate of COVID-19 so low, as to fail to account for the obviously high mortality seen in New York 19 , have received so many comments that they might never get published in a traditional journal, quite appropriately. See Table 1 for a comparison of preprints and traditional research publications. Summarizing the Literature: Blog posts as narrative reviews Review articles serve to synthesize the primary literature into a sometimes coherent overview of all the data. Systematic reviews and meta-analyses provide a quantitative synthesis of the published data, and narrative reviews provide a qualitative synthesis, altogether helping the reader make sense of the knowledge in any particular field. With the explosion in data becoming available for COVID-19, these reviews are sorely needed and will be valuable for most readers, who cannot sift individually through the China, seemed to suggest that the incidence of AKI was low, at about 2-5%. Hence the initial focus in the pandemic preparation for hospitals was more around ventilator shortages and not dialysis. However, data out of New York and Louisiana suggested otherwise, and a shortage of dialysis machines, supplies, and manpower became apparent in April 21, 22 . As the preprints and publications from these centres came online, the NephJC blog post was updated to reflect the much higher incidence of AKI: approximately 20% of critically ill patients need kidney replacement therapy 23 . As with preprints, a common criticism is that blog posts are not peer reviewed. ) information is spread at staggering rates: twenty-two COVID-19-related Tweets were shared per second as of early April 2020. 30 But whose voices are the loudest and which ones are accurate? Beyond social media, the concern with research being posted on preprint servers is that with lay people sifting through these sources, they could take the published results at face value, which could be a greater problem with interventional studies of pharmacotherapy. Perceived trustworthiness and expertise of a message's source correlate with the influence it will have. 31, 32 Health professionals can amplify credible work 33 NephJC, to review the science, which clearly did not support the speculation, and present the data on a blog page 45 . It lead to the formation of a "COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group" (hereon referred to as simply the COVID and ACE2 Working Group) , which has since published response papers 46, 47, 48 and continues to compile emerging evidence on hypertension therapies in COVID-19 onto the NephJC blog. The blog has had over 300,000 pageviews just in the month of March 2020 ( Figure 1B) , supporting both the widespread interest in this topic, and the ability of a free, easily accessible blogpost to satisfy this hunger for information. More than ten major professional societies in nephrology and cardiology have also responded, issuing statements recommending that patients prescribed these medications should continue taking them. Subsequent observational studies have reported no increase in morbidity or mortality for ACE inhibitors and ARBs in COVID-19 [49] [50] [51] [52] , and several RCTs are ongoing . This message, summarized in a recent World Health Organization (WHO) Scientific Brief 53 , has been echoed in physicians blog posts that have been shared widely on social media. 54 Coalescence of new kidney-related information during COVID19 For over ten years, the online nephrology community has been pioneering different modalities to virtually assemble and discuss topics in nephrology. 55, 56 These include NephMadness 57 , the yearly, friendly nephrology competition, and NephJC 58, 59 , a Twitter-based journal club that typically occurs over three spaced sessions to ensure global accessibility. Unsurprisingly, health care professionals obtain most of their updates regarding COVID-19 via social media. 60 With its numerous active members, the nephrology Twittersphere (NephTwitter) organically transformed into space to discuss kidney-related COVID-19 content. Early in the pandemic, anecdotal reports of AKI and hyperkalemia in COVID-19 arose. This is a (Table 2 ). Other groups maintain parallel curated pages on kidney disease and dialysis issues in COVID-19, such as on UpToDate 55 and in a living systematic review in the Annals of Internal Medicine. 64 In sum, the nephrology community has united through social media to critically appraise published and non-peer reviewed literature, culminating in the dissemination of pertinent information and focused advocacy efforts. The concerns about the quantity and quality of preprints also apply to the peer reviewed literature, especially during these times. Many journals have responded to the pandemic by fast-tracking COVID-19 research, which is a laudable goal, but can lead to errors slipping by the peer reviewer and editors. As an example, a single centre, peer-reviewed and published study from Wuhan reported no acute kidney injury (AKI) from COVID-19 67 , despite data from preprints from the same institute reporting mortality from AKI. 68, 69 Another large database study, peer reviewed and published in the Lancet, reported a 15% higher absolute all cause mortality with hydroxychloroquine usage in COVID-19. 70 Largely through Twitter and blogs 71 , the findings of this study were critiqued as being implausible, with one correction, a subsequent expression of concern, and a retraction 72 , all within 14 days (in contrast to 12 years for another infamous retraction 73 ). Another paper from the same purported database on the use of ACEi and ARBs also got flagged with an expression of concern 74 followed by a retraction 75 . These two studies were published in the medical journals with the highest impact factors, and were peer reviewed. COVID-19-Related Web Search Behaviors and Infodemic Attitudes in Italy: Infodemiological Study. JMIR Public Health and Surveillance How to fight an infodemic. The Lancet Preprint Servers in Kidney Disease Research: A Rapid Review. CJASN Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility. The Lancet Global Health A Systematic Review of COVID-19 Epidemiology Based on Current Evidence Covid-19 is reshaping the world of bioscience publishing -STAT Preprints come to life New preprint server for medical research The preprint dilemma Preprint Server Use in Kidney Disease Research: A Rapid Review Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag. bioRxiv Open peer-review platform for COVID-19 preprints Quick retraction of coronavirus paper was good moment for science Re: Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study The Right Seized It How swamped preprint servers are blocking bad coronavirus research Preprinting a pandemic: the role of preprints in the COVID-19 pandemic. bioRxiv Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. medRxiv The infection fatality rate of COVID-19 inferred from seroprevalence data. medRxiv Acute kidney injury in patients hospitalized with COVID-19 Acute Kidney Injury Associated with Coronavirus Disease Management of acute kidney injury in patients with COVID-19. The Lancet Respiratory Medicine Top Concerns of Tweeters During the COVID-19 Pandemic: Infoveillance Study Using Social Media to Mine and Analyze Public Opinion Related to COVID-19 in China Experimental evidence of massive-scale emotional contagion through social networks The pandemic of social media panic travels faster than the COVID-19 outbreak Twitter and YouTube issue joint statement on misinformation Facebook Deleting Coronavirus Posts, Leading To Charges Of Censorship Building trust while influencing online COVID-19 content in the social media world. Lancet Digit Health Using social and behavioural science to support COVID-19 pandemic response Going viral: how to boost the spread of coronavirus science on social media Going viral: doctors must tackle fake news in the covid-19 pandemic Digital technology and COVID-19 World leaders' usage of Twitter in response to the COVID-19 pandemic: a content analysis En cas de fièvre, prenez du paracétamol. Si vous êtes déjà sous anti-inflammatoires ou en cas de doute, demandez conseil à votre médecin Covid-19: European drugs agency to review safety of ibuprofen COVID-19 Update; A Message From Concerned Physicians See Which States and Cities Have Told Residents to Stay at Home. The New York Times Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Coronavirus Disease 2019 (COVID 19) and -Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin Converting Enzyme -Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection We need sound science and clinical trials, not simplistic and misleading algorithms Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19 Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19 Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19 COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers Don't Forget The Bubbles The Social Media Revolution in Nephrology Education An introduction and guide to becoming a social media savvy nephrologist NephMadness: Lessons from Seven Years on the Leading Edge of Social Media Medical Education Twitter-Based Journal Clubs: Additional Facts and Clarifications The Evolution of the Journal Club: From Osler to Twitter Knowledge and Perceptions of COVID-19 Among Health Care Workers: Cross-Sectional Study The Novel Coronavirus 2019 epidemic and kidneys NephJC Transcript: COVID and the Kidneys Coronavirus disease 2019 (COVID-19): Issues related to kidney disease and hypertension Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney International Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan Clinical characteristics of 101 COVID-19 nonsurvivors in Wuhan, China: a retrospective study. medRxiv Misleading Numbers: Is the Risk of Acute Kidney Injury with COVID-19 Truly This Low? Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet. 2020;0(0) This one's for the Lancet editorial board: A trolley problem for our times (involving a plate of delicious cookies and a steaming pile of poop) « Statistical Modeling, Causal Inference, and Social Science Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis RETRACTED: Ileal-lymphoid-nodular hyperplasia, nonspecific colitis, and pervasive developmental disorder in children. The Lancet Expression of Concern: Mehra MR et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 Social media, medicine and the modern journal club Fortifying the Corrective Nature of Post-publication Peer Review: Identifying Weaknesses, Use of Journal Clubs, and Rewarding Conscientious Behavior Robert Califf and the Rise of Medicine's Peanut Gallery. 33 Charts Peer Review: How We Found 15 Million Hours of Lost Time | AJE Statistical Review of Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. Zenodo